Literature DB >> 17505553

Means, motive, and opportunity: establishing culpability in pharmacoresistant epilepsy.

Graeme J Sills.   

Abstract

Entities:  

Year:  2007        PMID： 17505553      PMCID： PMC1867085          DOI： 10.1111/j.1535-7511.2007.00166.x

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  13 in total

1.  Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures.

Authors:  Holger A Volk; Wolfgang Löscher
Journal:  Brain       Date:  2005-02-16       Impact factor: 13.501

Review 2.  Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  Prog Neurobiol       Date:  2005-05       Impact factor: 11.685

3.  A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine.

Authors:  Nicola Marchi; Giovanna Guiso; Massimo Rizzi; Susanne Pirker; Klaus Novak; Thomas Czech; Christoph Baumgartner; Damir Janigro; Silvio Caccia; Annamaria Vezzani
Journal:  Epilepsia       Date:  2005-10       Impact factor: 5.864

Review 4.  Potential role of drug transporters in the pathogenesis of medically intractable epilepsy.

Authors:  Patrick Kwan; Martin J Brodie
Journal:  Epilepsia       Date:  2005-02       Impact factor: 5.864

Review 5.  Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms.

Authors:  Dieter Schmidt; Wolfgang Löscher
Journal:  Epilepsia       Date:  2005-06       Impact factor: 5.864

Review 6.  Drug resistance in brain diseases and the role of drug efflux transporters.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  Nat Rev Neurosci       Date:  2005-08       Impact factor: 34.870

7.  Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy.

Authors:  S M Sisodiya; W-R Lin; B N Harding; M V Squier; M Thom
Journal:  Brain       Date:  2002-01       Impact factor: 13.501

8.  Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy.

Authors:  Monica A Summers; J Layne Moore; James W McAuley
Journal:  Ann Pharmacother       Date:  2004-08-24       Impact factor: 3.154

9.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Authors:  A H Schinkel; E Wagenaar; C A Mol; L van Deemter
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

10.  Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance.

Authors:  Massimo Rizzi; Silvio Caccia; Giovanna Guiso; Cristina Richichi; Jan A Gorter; Eleonora Aronica; Marisa Aliprandi; Renzo Bagnati; Roberto Fanelli; Maurizio D'Incalci; Rosario Samanin; Annamaria Vezzani
Journal:  J Neurosci       Date:  2002-07-15       Impact factor: 6.167
View more
  1 in total

Review 1.  Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.

Authors:  Wolfgang Löscher; Oliver Langer
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.